OPTICUL DIAGNOSTICS, INC. is pioneering accessible, cost-effective microorganism detection for clinical labs and beyond, with unmatched specificity, sensitivity, and speed. Founded in 2007, Opticul Diagnostics specializes in the field of In Vitro diagnostics by focusing on accessible and affordable clinical laboratory and point-of-care (POC) microorganism identification without relying on reagents. Their technology ensures specific, sensitive, and rapid identification, with potential applications in areas such as homeland security, combat conditions, clean tech, and the monitoring of instrument contamination.
The latest investment of $450.00K was a Seed Round investment at 09 September 2014 by BATM Ltd. This injection of capital has the potential to steer Opticul Diagnostics towards further success and innovation, particularly in expanding their reach within the clinical lab and point-of-care microorganism identification markets. The confidence shown by BATM Ltd through this investment serves as validation for the potential of Opticul Diagnostics' technologies and applications.
Opticul Diagnostics' novel approach to microorganism detection has the potential to revolutionize In Vitro diagnostics and related fields, making them an intriguing prospect for potential investors seeking opportunities within the healthcare technology sector.
